CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Down 9.4% in September

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 146,500 shares, a drop of 9.4% from the September 15th total of 161,700 shares. Based on an average daily trading volume, of 34,400 shares, the short-interest ratio is presently 4.3 days. Approximately 3.4% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on CASI Pharmaceuticals in a report on Saturday, August 3rd. They issued a “hold” rating for the company.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC raised its stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 10.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 40,800 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.30% of CASI Pharmaceuticals worth $224,000 as of its most recent SEC filing. 22.23% of the stock is owned by hedge funds and other institutional investors.

CASI Pharmaceuticals Stock Performance

Shares of NASDAQ CASI traded down $0.18 during midday trading on Wednesday, hitting $5.40. The company’s stock had a trading volume of 18,212 shares, compared to its average volume of 151,263. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.36 and a current ratio of 3.88. CASI Pharmaceuticals has a 1-year low of $2.05 and a 1-year high of $8.48. The firm’s fifty day moving average price is $6.31 and its 200-day moving average price is $4.86. The firm has a market cap of $72.37 million, a P/E ratio of -2.37 and a beta of 0.69.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Friday, August 16th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The company had revenue of $3.98 million during the quarter, compared to the consensus estimate of $4.43 million. CASI Pharmaceuticals had a negative return on equity of 126.20% and a negative net margin of 118.81%.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.